Abstract
Alzheimers disease (AD) is a progressive, neurodegenerative disorder that results in severe cognitive decline. Amyloid plaques are a principal pathology found in AD and are composed of aggregated amyloid- beta (Aβ) peptides. According to the amyloid hypothesis, Aβ peptides initiate the other pathologies characteristic for AD including cognitive deficits. Immunotherapy against Aβ is a potential therapeutic for the treatment of humans with AD. While anti-Aβ immunotherapy has been shown to reduce amyloid burden in both mouse models and in humans, immunotherapy also exacerbates vascular pathologies. Cerebral amyloid angiopathy (CAA), that is, the accumulation of amyloid in the cerebrovasculature, is increased with immunotherapy in humans with AD and in mouse models of amyloid deposition. CAA persists in the brains of clinical trial patients that show removal of parenchymal amyloid. Mouse model studies also show that immunotherapy results in multiple small bleeds in the brain, termed microhemorrhages. The neurovascular unit is a term used to describe the cerebrovasculature and its associated cells-astrocytes, neurons, pericytes and microglia. CAA affects brain perfusion and there is now evidence that the neurovascular unit is affected in AD when CAA is present. Understanding the type of damage to the neurovascular unit caused by CAA in AD and the underlying cause of microhemorrhage after immunotherapy is essential to the success of therapeutic vaccines as a treatment for AD.
Keywords: Immunotherapy, Microhemorrhages, Vascular Pathology, Transgenic Mice, Aβ peptides, amyloid hypothesis
CNS & Neurological Disorders - Drug Targets
Title: Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
Volume: 8 Issue: 1
Author(s): Donna M. Wilcock and Carol A. Colton
Affiliation:
Keywords: Immunotherapy, Microhemorrhages, Vascular Pathology, Transgenic Mice, Aβ peptides, amyloid hypothesis
Abstract: Alzheimers disease (AD) is a progressive, neurodegenerative disorder that results in severe cognitive decline. Amyloid plaques are a principal pathology found in AD and are composed of aggregated amyloid- beta (Aβ) peptides. According to the amyloid hypothesis, Aβ peptides initiate the other pathologies characteristic for AD including cognitive deficits. Immunotherapy against Aβ is a potential therapeutic for the treatment of humans with AD. While anti-Aβ immunotherapy has been shown to reduce amyloid burden in both mouse models and in humans, immunotherapy also exacerbates vascular pathologies. Cerebral amyloid angiopathy (CAA), that is, the accumulation of amyloid in the cerebrovasculature, is increased with immunotherapy in humans with AD and in mouse models of amyloid deposition. CAA persists in the brains of clinical trial patients that show removal of parenchymal amyloid. Mouse model studies also show that immunotherapy results in multiple small bleeds in the brain, termed microhemorrhages. The neurovascular unit is a term used to describe the cerebrovasculature and its associated cells-astrocytes, neurons, pericytes and microglia. CAA affects brain perfusion and there is now evidence that the neurovascular unit is affected in AD when CAA is present. Understanding the type of damage to the neurovascular unit caused by CAA in AD and the underlying cause of microhemorrhage after immunotherapy is essential to the success of therapeutic vaccines as a treatment for AD.
Export Options
About this article
Cite this article as:
Wilcock M. Donna and Colton A. Carol, Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice, CNS & Neurological Disorders - Drug Targets 2009; 8 (1) . https://dx.doi.org/10.2174/187152709787601858
DOI https://dx.doi.org/10.2174/187152709787601858 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>Drosophila melanogaster</i> a Versatile Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Neuropharmacology The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Current Alzheimer Research Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Current Medicinal Chemistry Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities
Current Neuropharmacology Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Oxidant/Antioxidant Imbalance and the Risk of Alzheimer's Disease
Current Alzheimer Research Experimental Models of Discovery: Prediction and Protection must Proceed “Hand-in-Hand”
Current Neurovascular Research Role of Oxidative Stress and Metal Toxicity in the Progression of Alzheimer’s Disease
Current Neuropharmacology Relapsing Remitting Multiple Sclerosis and its Relationship with the Immune System and Oxidative Stress
Current Immunology Reviews (Discontinued) Brain Drug Delivery: Overcoming the Blood-brain Barrier to Treat Tauopathies
Current Pharmaceutical Design The AMP-Activated Protein Kinase: Role in Regulation of Skeletal Muscle Metabolism and Insulin Sensitivity
Mini-Reviews in Medicinal Chemistry Prophylaxis and Post-exposure Treatment of Intoxications Caused by Nerve Agents and Organophosphorus Pesticides
Mini-Reviews in Medicinal Chemistry Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging
Current Medicinal Chemistry Gene Therapy for the Peripheral Nervous System: A Strategy to Repair the Injured Nerve?
Current Gene Therapy Editorial (Thematic Issue: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications)
CNS & Neurological Disorders - Drug Targets Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design